Haopy Pharmaceutical Group
Founded in 1999, Haopy Pharmaceutical Group is a company deeply rooted in the biopharmaceutical and big health fields. It operates across the entire industrial chain, encompassing rare medicinal plant conservation and application, new drug research and development, pharmaceutical production, drug distribution, public warehousing and distribution service, public food testing service, public medical imaging diagnostics and precision medical services, international cooperation in the pharmaceutical industry under the "Belt and Road" initiative, AI-assisted medical diagnosis, and internet + healthcare. Upholding the corporate mission of "National, Chinese, International", Haopy group consistently focuses on five major innovation platforms: big health, Internet + healthcare, intelligent pharmaceutical logistics, drug R&D, and intellectual property protection and operation. It aims to build a national pharmaceutical brand with a focus on traditional Chinese medicine, promote equitable access to medical resources to redefine health concepts, advance biodiversity conservation in line with Haopy's vision, and support rural revitalization through the cultivation of specialty medicinal plants.
Haopy Pharmaceutical Group continues to prioritize innovation. In terms of product innovation, its Class 1.1 new drug project has completed Phase II clinical trials, making it the only project in Yunnan Province to be consecutively included in the national "11th Five-Year," "12th Five-Year," and "13th Five-Year" major new drug development programs. The Group's self-developed product, Bulleyaconitine A Tablets, is the world's first state-dependent sodium channel blocker and a novel Class III analgesic drug. Haopy has held invention patents in nine countries. In terms of business model innovation, Haopy's public pharmaceutical logistics center, the largest public service platform in Yunnan province, has incubated nearly 920 different pharmaceutical and medical device companies. In terms of industry innovation, Haopy established Yunnan's first public medical imaging center, precision medical platform, and Internet hospital, dedicated to providing high-quality independent medical imaging diagnostics, refined physical examinations, and early cancer screening service, while driving the digital transformation of traditional pharmaceutical industry in Yunnan province.
Haopy Pharmaceutical Group currently serves as the executive president unit of the National Pharmaceutical Industry Chamber of Commerce and the president unit of the Yunnan Pharmaceutical Industry Chamber of Commerce. It has been recognized as one of "China's Top 100 Pharmaceutical Manufacturers," "China's Top 100 Pharmaceutical Distributors," "Outstanding National Ethnic Medicine Brand," "National Intellectual Property Advantage Enterprise," and "Most Socially Responsible Enterprise." the Chairman, Mr. Li Biao has been awarded the "National May 1st Labor Medal" and "Top 10 National Pharmaceutical Industry Leaders," etc.